JP4391087B2 - 癌の処置のための薬学的組み合わせ - Google Patents

癌の処置のための薬学的組み合わせ Download PDF

Info

Publication number
JP4391087B2
JP4391087B2 JP2002574985A JP2002574985A JP4391087B2 JP 4391087 B2 JP4391087 B2 JP 4391087B2 JP 2002574985 A JP2002574985 A JP 2002574985A JP 2002574985 A JP2002574985 A JP 2002574985A JP 4391087 B2 JP4391087 B2 JP 4391087B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
formula
cancer
compound
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002574985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525142A5 (enExample
JP2004525142A (ja
Inventor
フランシス・ジェイ・ジャイルズ
ハゴップ・エム・カンタージャン
ジャック・ジョリヴェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of JP2004525142A publication Critical patent/JP2004525142A/ja
Publication of JP2004525142A5 publication Critical patent/JP2004525142A5/ja
Application granted granted Critical
Publication of JP4391087B2 publication Critical patent/JP4391087B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2002574985A 2001-03-23 2002-03-25 癌の処置のための薬学的組み合わせ Expired - Fee Related JP4391087B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27797501P 2001-03-23 2001-03-23
US33060101P 2001-10-25 2001-10-25
PCT/CA2002/000426 WO2002076472A2 (en) 2001-03-23 2002-03-25 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs

Publications (3)

Publication Number Publication Date
JP2004525142A JP2004525142A (ja) 2004-08-19
JP2004525142A5 JP2004525142A5 (enExample) 2005-12-22
JP4391087B2 true JP4391087B2 (ja) 2009-12-24

Family

ID=26958821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574985A Expired - Fee Related JP4391087B2 (ja) 2001-03-23 2002-03-25 癌の処置のための薬学的組み合わせ

Country Status (13)

Country Link
US (2) US6800639B2 (enExample)
EP (1) EP1370270B1 (enExample)
JP (1) JP4391087B2 (enExample)
KR (1) KR20040018341A (enExample)
AT (1) ATE450265T1 (enExample)
CA (1) CA2441568A1 (enExample)
DE (1) DE60234577D1 (enExample)
HU (1) HUP0400314A3 (enExample)
MX (1) MXPA03008623A (enExample)
NO (1) NO20034204L (enExample)
NZ (1) NZ528394A (enExample)
PL (1) PL365285A1 (enExample)
WO (1) WO2002076472A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
KR20110102485A (ko) * 2002-07-30 2011-09-16 아에테르나 젠타리스 게엠베하 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품
WO2004052369A1 (en) * 2002-12-06 2004-06-24 Shire Biochem Inc. Pharmaceutical combinations and methods for the treatment of leukemia
CA2527126A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
SI2263694T1 (sl) * 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
CN104739841B (zh) 2008-01-11 2018-06-01 里亚塔医药公司 合成三萜类化合物及用以治病之方法
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20100004193A1 (en) * 2008-07-07 2010-01-07 Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare Combination therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
JP7337539B2 (ja) 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6630480B1 (en) * 1999-03-29 2003-10-07 Biochem Pharma Inc. Methods of treating leukemia
HUP0301363A2 (hu) * 2000-10-13 2005-12-28 Shire Biochem Inc. Javított intercelluláris bejuttathatóságú dioxolán analógok
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine

Also Published As

Publication number Publication date
WO2002076472A3 (en) 2003-04-10
NZ528394A (en) 2005-06-24
EP1370270B1 (en) 2009-12-02
US6800639B2 (en) 2004-10-05
NO20034204L (no) 2003-11-21
KR20040018341A (ko) 2004-03-03
CA2441568A1 (en) 2002-10-03
US20050004081A1 (en) 2005-01-06
WO2002076472A2 (en) 2002-10-03
JP2004525142A (ja) 2004-08-19
HUP0400314A3 (en) 2006-02-28
US20030083316A1 (en) 2003-05-01
PL365285A1 (en) 2004-12-27
NO20034204D0 (no) 2003-09-22
EP1370270A2 (en) 2003-12-17
ATE450265T1 (de) 2009-12-15
DE60234577D1 (de) 2010-01-14
MXPA03008623A (es) 2004-05-21
HUP0400314A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
JP4391087B2 (ja) 癌の処置のための薬学的組み合わせ
KR100675044B1 (ko) 부작용 경감제
ES2333399T3 (es) Metodos para tratar una leucemia.
JP2002540142A5 (enExample)
US20100087458A1 (en) Method of treating melanoma
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
TW201630597A (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
US6645972B2 (en) Methods of treating leukemia
US20030027799A1 (en) Methods of treating cancer using a combination of drugs
AU2002336864A1 (en) Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
US20220395575A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
AU2002245972A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
WO1998021956A1 (en) Heregulin antagonists and methods for their use
HK40061085A (en) Novel therapeutic method and novel therapeutic agent for hematological cancer
JP4395901B2 (ja) 新規遺伝子治療用薬剤
TW202203942A (zh) 血液癌之新穎治療法及新穎治療劑
CN1744902B (zh) 治疗癌症的药物组合
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090908

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091007

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121016

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131016

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131016

Year of fee payment: 4

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees